Investor Relations

Investor FAQs

Marrone Bio Innovations, Inc. is a leading global provider of bio-based pest management and plant health products for the agricultural, turf and ornamental and water treatment markets. Pioneers in natural product development, Marrone Bio Innovations has created an industry leading platform of biopesticides that address the growing global demand for effective, efficient, and environmentally responsible products. The company markets multiple commercial products, has built a deep pipeline of advanced and early stage products, and has amassed an extensive library of microorganisms and plant extracts that have been screened for pipeline candidates.

MBI trades on the NASDAQ under the ticker symbol MBII.

MBI was incorporated 2006.

1540 Drew Ave.
Davis, CA 95618

Main Phone: (530) 750-2800

US Toll Free: (877) 664-4476

MBI’s fiscal year ends December 31.

August 2, 2013

Jefferies and Piper Jaffray acted as book-running managers for the offering and Baird and Stifel acted as co-managers for the offering.

A copy of the final prospectus related to the IPO may be obtained from Jefferies LLC, Equity Syndicate Prospectus Department, at 520 Madison Avenue, New York, New York, 10022, or by calling (877) 547-6340, or by emailing Prospectus_Department@Jefferies.com, and from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by calling (800) 747-3924 or by emailing prospectus@pjc.com.

MBI does not currently have a direct stock purchase plan.

As a company that trades publicly on the NASDAQ, shares can be bought and sold through your registered representative.

Visit the Events page in the IR section of our website for information on upcoming calls.  Information will be posted as available.

No, MBI does not intend to declare or pay cash dividends on its capital stock in the foreseeable future.

MBI is closed to the public and does not offer tours.

We receive a large number of requests for information in connection with student projects, and unfortunately are not able to respond to each one individually. This web site, however, contains answers to many of the most commonly asked questions about MBI, our technology, and the work we are doing.

Additional information may be obtained by reading our SEC filings.

Now that the IPO is completed, please contact your broker or financial advisor for advice on how to handle this transaction.

American Stock Transfer & Trust Company

If you are a stockholder of record, please contact MBI s transfer agent at:
 
American Stock Transfer & Trust Company
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449
Greg Falesnik
Managing Director (MZ North America)
949-385-6449
 

Please submit your question using the form below. * Required fields

 
 
 
 
 
 
This helps Marrone Bio Innovations prevent automated submissions.